Results
|
|
3661.
|
|
|
|
3662.
|
|
|
|
3663.
|
|
|
|
3664.
|
|
|
|
3665.
|
Design of potent inhibitors of human beta-secretase. Part 1. [electronic resource] by
- Freskos, John N
- Fobian, Yvette M
- Benson, Timothy E
- Bienkowski, Michael J
- Brown, David L
- Emmons, Thomas L
- Heintz, Robert
- Laborde, Alice
- McDonald, Joseph J
- Mischke, Brent V
- Molyneaux, John M
- Moon, Joseph B
- Mullins, Patrick B
- Bryan Prince, D
- Paddock, Donna J
- Tomasselli, Alfredo G
- Winterrowd, Gregory
Producer: 20070424
In:
Bioorganic & medicinal chemistry letters vol. 17
Availability: No items available.
|
|
|
3666.
|
|
|
|
3667.
|
|
|
|
3668.
|
|
|
|
3669.
|
Mass-tag technology responding to intracellular signals as a novel assay system for the diagnosis of tumor. [electronic resource] by
- Kang, Jeong-Hun
- Katayama, Yoshiki
- Han, Aishan
- Shigaki, Shuhei
- Oishi, Jun
- Kawamura, Kenji
- Toita, Riki
- Han, Xiao Ming
- Mori, Takeshi
- Niidome, Takuro
Producer: 20070402
In:
Journal of the American Society for Mass Spectrometry vol. 18
Availability: No items available.
|
|
|
3670.
|
|
|
|
3671.
|
|
|
|
3672.
|
|
|
|
3673.
|
|
|
|
3674.
|
|
|
|
3675.
|
|
|
|
3676.
|
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. [electronic resource] by
- Piedbois, P
- Serin, D
- Priou, F
- Laplaige, P
- Greget, S
- Angellier, E
- Teissier, E
- Berdah, J-F
- Fabbro, M
- Valenza, B
- Herait, P
- Jehl, V
- Buyse, M
Producer: 20070405
In:
Annals of oncology : official journal of the European Society for Medical Oncology vol. 18
Availability: No items available.
|
|
|
3677.
|
|
|
|
3678.
|
|
|
|
3679.
|
|
|
|
3680.
|
|